Abstract
This study compared the release behavior of single-unit (tablets, capsules) and multiple-unit (minitablets in capsules) controlled-release systems of furosemide. The swelling and erosion behaviors of these systems, which contained the swellable hydrophilic polymers sodium alginate (high viscosity) and Carbopol 974P, were compared. Swelling and erosion experiments showed a high degree of swelling and limited erosion for the Carbopol preparations, whereas less swelling but greater erosion was observed for the sodium alginate preparations. The sodium alginate preparations were eroded in 6 hours, while Carbopol preparations exhibited limited erosion within this period of time. These results appear to be attributed to the physicochemical characteristics of the polymers used in this study. Polymer characteristics greatly influenced the release of furosemide (model drug) from the formulations prepared and tested. Sodium alginate had a less pronounced sustained release effect compared with Carbopol (ie, in 8 hours all 3 sodium alginate dosage forms displayed complete release of furosemide, while only 30% of the drug was released from Carbopol dosage forms). Finally, all 3 Carbopol dosage forms (single- and multiple-unit) displayed similar release behavior while sodium alginate dosage forms displayed a different and more distinctive behavior. Minitablets and tablets showed a greater sustained release effect compared with capsules. Evaluation of the release data indicates that the release mechanism for sodium alginate formulations may be attributed to erosion/dissolution, while for Carbopol it may be attributed mainly to polymer relaxation and diffusion of the drug from the polymer surface.
KeyWords: Single-unit, Multiple-unit, Minitablets, Controlled release, Carbopol, Sodium alginate, Furosemide
Full Text
The Full Text of this article is available as a PDF (280.3 KB).
References
- 1.Follonier N, Doelker E. Biopharmaceutical comparison of oral multiple-unit and single-unit sustained-release dosage forms. STP Pharma Sciences. 1992;2:141–155. [Google Scholar]
- 2.Vial-Bernasconi AC, Doelker E, Buri P. Prolonged release capsules: divided and monolithic forms. STP Pharma Sciences. 1988;4:397–409. [Google Scholar]
- 3.Fan LT, Singh SK. Introduction. In: Fan LT, Singh SK, editors. Controlled Release-A Quantitative Treatment. Berlin, Germany: Springer-Verlag; 1989. pp. 4–5. [Google Scholar]
- 4.Fan LT, Singh SK. Diffusion-controlled release. In: Fan LT, Singh SK, editors. Controlled Release-A Quantitative Treatment. Berlin, Germany: Springer-Verlag; 1989. pp. 61–79. [Google Scholar]
- 5.Fan LT, Singh SK. Introduction. In: Fan LT, Singh SK, editors. Controlled Release-A Quantitative Treatment. Berlin, Germany: Springer-Verlag; 1989. pp. 3–3. [Google Scholar]
- 6.Ojantakanen S. Effect of viscosity grade of polymer additive and compression force on release of ibuprofen from hard gelatin capsules. Acta Pharm Fenn. 1992;101:119–126. [Google Scholar]
- 7.Efentakis M, Vlachou M. Evaluation of high molecular weight poly(oxyethylene) (polyox) polymer: studies of flow properties and release rates of furosemide and captopril from controlled release hard gelatin capsules. Pharm Dev Technol. 2000;5:339–346. doi: 10.1081/PDT-100100549. [DOI] [PubMed] [Google Scholar]
- 8.Digenis GA. The in vivo behavior of multiparticulate versus single unit dosage formulations. In: Ghebre-Sellassie I, editor. Multipaticulate Oral Drug Delivery. New York: Marcel Dekker, Inc.; 1994. pp. 333–355. [Google Scholar]
- 9.Celik M. Compaction of multiparticulate oral dosage forms. In: Ghebre-Sellassie I, editor. Multipaticulate Oral Drug Delivery. New York: Marcel Dekker, Inc.; 1994. pp. 181–215. [Google Scholar]
- 10.Coupe AJ, Davis SS, Wilding IR. Variation in gastrointestinal transit of pharmaceutical dosage forms in healthy subjects. Pharm Res. 1991;8:360–364. doi: 10.1023/A:1015849700421. [DOI] [PubMed] [Google Scholar]
- 11.Lowman AM, Peppas NA. Hydrogels. In: Mathiowitz E, editor. Encyclopedia of Controlled Drug Delivery. New York: John Wiley and Sons, Inc.; 1999. pp. 407–407. [Google Scholar]
- 12.Alderman D. A review of cellulose ethers in hydrophilic matrices for oral controlled-release dosage forms. Int J Pharm Technol Prod Manuf. 1984;5:1–9. [Google Scholar]
- 13.Hogan JE. Hydropropylmethycellulose sustained release technology. Drug Dev Ind Pharm. 1989;15:975–999. doi: 10.3109/03639048909043660. [DOI] [Google Scholar]
- 14.McNeely W, Pettitt D. Alginates. In: Whistler R, Bemiller J, editors. Industrial Gums. New York: Academic Press; 1973. pp. 68–71. [Google Scholar]
- 15.Sugawara S, Imai T, Otagiri M. The controlled release of prednisolone using alginate gel. Pharm Res. 1994;11:272–277. doi: 10.1023/A:1018963626248. [DOI] [PubMed] [Google Scholar]
- 16.Controlled release tablets and capsules. Carbopol Technical Bulletin. 1994;17:1–27.
- 17.Perez-Marcos B, Ford JL, Armstrong DJ, Elliot PN, Rostron C, Hogan JE. Influence of pH on the release of propranolol hydrochloride from matrices containing hydroxypropyl methylcellulose K4M and Carbopol 974. J Pharm Sci. 1996;85:330–334. doi: 10.1021/js950359z. [DOI] [PubMed] [Google Scholar]
- 18.Apicella A, Cappello B, Del Nobile M, La Rontonda MI, Mensitieri G, Nicolais L. Poly(ethylene oxide) (PEO) and different molecular weight PEO blends monolithic devices for drug release. Biomaterials. 1993;14:83–91. doi: 10.1016/0142-9612(93)90215-N. [DOI] [PubMed] [Google Scholar]
- 19.Khan Z, Jiabi Z. Formulation and in vitro evaluation of ibuprofen-carbopol 974-NF controlled release matrix tablets. J. Control Release. 1998;54:185–190. doi: 10.1016/S0168-3659(97)00225-3. [DOI] [PubMed] [Google Scholar]
- 20.Korsmeyer RW, Gurny R, Doelker E, Buri P, Peppas NA. Mechanisms of solute release from porous hydrophilic polymers. Int J Pharm. 1983;15:25–35. doi: 10.1016/0378-5173(83)90064-9. [DOI] [PubMed] [Google Scholar]
- 21.Khan K. The concept of dissolution efficiency. J Pharm Pharmacol. 1975;27:48–49. doi: 10.1111/j.2042-7158.1975.tb09378.x. [DOI] [PubMed] [Google Scholar]
- 22.Prasad V, Rapaka R, Knight P, Cabana B. Dissolution medium: a critical parameter to identify bioavailability problems of furosemide tablets. Int J Pharm. 1982;11:81–92. doi: 10.1016/0378-5173(82)90180-6. [DOI] [Google Scholar]